Jazz Pharmaceuticals/Concert Pharmaceuticals Start Study - Analyst Blog

By
A A A

Jazz Pharmaceuticals ( JAZZ ) and partner Concert Pharmaceuticals, Inc. ( CNCE ) announced the initiation of a phase I study (n=28) on JZP-386, a deuterated version of sodium oxybate (the active ingredient in Xyrem). Xyrem is marketed by Jazz Pharma in the U.S. for the treatment of cataplexy and excessive daytime sleepiness in patients suffering from narcolepsy.

The phase I study will be evaluating the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JZP-386. The study will also include Xyrem as an active control. The primary objective of the study is to identify safe and tolerable dose/doses of JZP-386 to be used in subsequent clinical studies. Jazz Pharma will also evaluate whether JZP-386 is appropriate for once nightly dosing.

We remind investors that Jazz Pharma and Concert Pharma collaborated in 2013 as per which the former gained the worldwide rights to develop and commercialize JZP-386. Concert Pharma, responsible for clinical activities of JZP-386 through phase I, is eligible to receive milestone payments and tiered royalties on any worldwide sales.

Xyrem contributed around 65.8% ($569.1 million) of net product sales of Jazz Pharma last year. Jazz Pharma is facing a series of patent challenges on the drug. The company is currently engaged in several litigations with generic drug makers of Xyrem. The sooner-than-expected entry of Xyrem generics would be a huge blow for the company.

The development of JZP-386 is primarily to protect Xyrem revenues. As a result, the successful development of JZP-386 is crucial for Jazz Pharma. The company's shares gained around 2.8% on the announcement of phase I study initiation on JZP-386.

Jazz Pharma holds a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Synergy Pharmaceuticals, Inc. ( SGYP ) and Actelion Ltd. ( ALIOF ). Both the stocks hold a Zacks Rank #1 (Strong Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

CONCERT PHARMA (CNCE): Free Stock Analysis Report

ACTELION LTD (ALIOF): Get Free Report

SYNERGY PHARMAC (SGYP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: JAZZ , CNCE , ALIOF , SGYP

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com